Management of GERD Gastritis in Pediatric Patients

Introduction to Guideline Recommendations

• The American Academy of Pediatrics recommends proton pump inhibitors (PPIs) as first-line therapy for pediatric GERD, with a weight-adjusted dose of 0.7-3.3 mg/kg/day, due to their superior efficacy in healing esophagitis and providing symptom relief compared to alternative agents 1, 2
• PPIs, such as rabeprazole, omeprazole, lansoprazole, and esomeprazole, are FDA-approved for use in pediatric patients, with specific age ranges and dosing recommendations 1, 2

Preferred Treatment Options

• The American Academy of Pediatrics guidelines establish PPIs as the most effective acid suppressants for pediatric GERD, with FDA approval for multiple agents in the 12-17 year age range 1, 2
• Rabeprazole 20 mg daily is FDA-approved for ages 12-17 years 1, 2
• Omeprazole, lansoprazole, and esomeprazole are approved for ages 1-17 years, with weight-based dosing of 0.7-3.3 mg/kg/day 1

Evidence Supporting PPI Use

• PPIs have been proven superior to H2-receptor antagonists (H2RAs) and placebo for healing erosive esophagitis and providing symptom relief in children 3, 2
• The American Academy of Pediatrics does not mention sucralfate in current pediatric GERD guidelines, indicating it is not considered a standard treatment option 1, 3, 4, 2

Treatment Algorithm

• Initial therapy should start with a single daily dose of PPI, taken 30-60 minutes before the first meal 5, 6
• For inadequate response, escalate to twice-daily PPI dosing before considering alternative agents 5, 6, 7
• Alginate-containing antacids provide rapid symptom relief for breakthrough symptoms 8
• H2RAs can be used as-needed for nighttime symptoms 1, 8

Lifestyle Modifications

• Elevate the head of the bed for nighttime symptoms 5, 6, 8
• Avoid meals within 2-3 hours of bedtime 5, 6, 8
• Weight management is recommended if the patient is overweight 5, 6, 8
• Avoid trigger foods that consistently provoke symptoms 7, 8

Critical Pitfalls to Avoid

• Do not use H2RAs as monotherapy when PPIs are available, due to their lower efficacy and development of tachyphylaxis within 6 weeks 3, 2
• Avoid metoclopramide due to its unfavorable risk-benefit profile 9, 7, 8
• Do not add nocturnal H2RA to twice-daily PPI therapy, as there is no evidence of improved efficacy 7, 8
• Be aware of the increased risk of liver disease and gynecomastia associated with cimetidine in children 3, 2